Cardiology Letters 2023, 32(1):49-53
Masked hypertension - diagnosis, treatment and prognosis
- 1 I. interná klinika, Lekárska fakulta Univerzita Komenského, Univerzitná nemocnica, Bratislava
- 2 Katedra fyzioterapie, Fakulta zdravotníckych vied Univerzita sv. Cyrila a Metoda, Trnava
- 3 Kardiologická klinika, Oddelenie neinvazívnej kardiológie, Národný ústav srdcových a cievnych chorôb, a. s., Bratislava, Slovenská republika
The diagnosis of masked hypertension has been made easier with the widespread availability of home blood pressure monitoring devices, as well as the routine use of ambulatory blood pressure monitoring. The negative impact of masked hypertension on cardiovascular morbidity and mortality is evidenced by numerous well-designed clinic-based and population-based studies. The relationship of masked hypertension and target organ damage is also well documented. These two factors, combined with the robust evidence of reduced cardiovascular morbidity and mortality achieved with blood pressure treatment, makes the argument for actively identifying patients with masked hypertension and prescribing treatment similar to that for patients with sustained hypertension.
Keywords: masked hypertension; masked uncontrolled hypertension; prevalence; clinical significance; treatment
Published: January 1, 2023 Show citation
References
- Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Barnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021-3104. DOI: 10.1093/eurheart/ehy339
Go to original source... - Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension 2002;40:795-796. DOI:10.1161/01. hyp.0000038733.08436.98
Go to original source... - Liu JE, Roman MJ, Pini R, Schwartz JE, Pickering TG, Devereux RB. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med. 1999;131:564-572. DOI:10.7326/0003-4819-1318-199910190-00003
Go to original source... - Magalhaes JA, Lins-Filho OL, Couto TLG, de FP Silva MV, Lustosa TC, Barroso WKS, et al. Prevalence of masked hypertension evaluated by home blood pressure monitoring in a large sample of patients with office blood pressure ˂ 140/90 mmHg. Blood Press Monit 2021;26:224-229. DOI:10.1097/MBP.0000000000000517
Go to original source... - Pierdomenico SD, Pierdomenico AM, Coccina F, Porreca E. Prognosis of masked and white coat uncontrolled hypertension detected by Ambulatory blood pressure monitoring in elderly treated hypertensive patients. Am J Hypertens 2017;30:11061111. DOI:10.1093/ajh/hpx104
Go to original source... - Aronow WS. Masked hypertension. Ann Transl Med 2017;5:456. DOI:10.21037/atm.2017.09.24
Go to original source... - Thakkar HV, Pope A, Anpalahan M. Masked hypertension: A systematic review. Heart Lung and Circulation 2020;29:102-111. DOI:10.1016/j.hlc.2019.08.006
Go to original source... - Li S, Schwartz JE, Shimbo D, Muntner P, Shikany JM, Booth 3rd JN, et al. Estimated prevalence of masked asleep hypertension in US adults. JAMA Cardiol 2021;6:568-573. DOI:10.1001/ jamacardio2020.5212
Go to original source... - Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Himmelfarb ChD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71(62017):e13-e115. DOI:10.1161/HYP.0000000000000065
Go to original source... - De la Sierra A, Banegas R, Vinyoles E, Segura J, Gorostidi M, de la Cruz J, et al. Prevalence of masked hypertension in untreated and treated patients with office blood pressure below 130/80 mmHg. Circulation 2018;137:2651-2653. DOI:10.1161/CIRCULATIONAHA.118.034619
Go to original source... - Schwartz JE, Burg MM, Shimbo D, Broderick JE, Stone AA, Ishikawa J, et al. Clinic blood pressure underestimates ambulatory blood pressure in untreated employer-based US population: Results from the Masked Hypertension Study. Circulation 2016;134:1794-1807. DOI:10.1161/CIRCULATIONAHA.116.023404
Go to original source... - Tientcheu D, Ayers C, Das SR, McGuire DK, de Lemos JA, Khera A, et al. Target organ complications and cardiovascular events associated with masked hypertension and whitecoat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol 2015;66:2159-2169. DOI:10.1016/j. jacc.2015.09.007
Go to original source... - Omboni S, Aristizabal, D, de la Sierra A, Dolan E, Head G, Kahan T, et al. Hypertension types defined by clinic and ambulatory blood pressure in 14 143 patients referred to hypertension clinics worldwide. Data from the ARTEMIS study. J Hypertens. 2016;34:2187-2198. DOI:10.1097/HJH.0000000000001074
Go to original source... - Presta V, Figliuzzi I, D´Agostino M, Citoni B, Miceli F, Simonelli F, et al. Nocturnal blood pressure patterns and cardiovascular outcomes in patients with masked hypertension. J Clin Hypertens (Greenwich). 2018;20:1238-1246. DOI:10.1111/jch.13361
Go to original source... - Aronow WS. Hypertension and left ventricular hypertrophy. Ann Transl Med 2017;5:310. DOI:10.21037atm.2017.06.14
Go to original source... - Pierdomenico SD, Pierdomenico AM, Coccina F, Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of masked uncontrolled hypertension: systematic review and meta-analysis. Hypertension 2018;72:862-869. DOI:10.1161/ HYPERTENSIONAHA.118.11499
Go to original source... - Zhang DY, Guo QH, De-Wei A, Li Y, Wang J-G. A comparative meta-analysis of prospective observational studies on masked hypertension and masked uncontrolled hypertension defined by ambulatory and home blood pressure. J Hypertens2019;37:1775-1785. DOI:10.1097/HJH.0000000000002109
Go to original source... - Van Vark LC, Bertrand M, Akkerhuis M, Brugts JJ, Fox K, Mourad J-J, el. al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012;33:2088-2097. DOI:10.1093/eurheartj/ehs075
Go to original source...

